Diversity among study participants in research eliminates health disparities and promotes precision medicine
SHC is committed to increasing diversity and inclusion in research by documenting the current gaps in participation and advocating for equity in precision medicine research. We will identify and share best practices of cancer centers that are successfully accruing diverse populations to their cancer trials. Through participation in clinical research, we believe that racial and ethnic minorities can benefit from the improved outcomes achieved with newer therapies and advance our understanding of disease heterogeneity across demographics for all Americans.
Find best practices and tools to promote the inclusion of diverse populations in research.
Are you searching for a clinical trial? – Featured Links from our Partners
Best practices for Sponsors and Sites
Regnante JM, Richie NA, Fashoyin-Aje L, Vichnin M, Ford ME, Roy UB, Turner K, Hall LL, González ET, Esnaola NF, Clark LT, Adams HC III, Alese OB, Gogineni K, McNeil LH, Petereit DG, Sargeant I, Dang JH, Obasaju C, Highsmith Q, Craddock Lee SJ, Hoover SC, Williams EL, Chen MS Jr.: US Cancer Centers of Excellence strategies for increased inclusion of racial and ethnic minorities in clinical trials. J Oncol Prac DOI 10.1200/JOP.18.00638 (open access)
Winkfield K, Cancer, October 2019.
Representative Populations in Publications
Loree, et al, Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals 2008 to 2018, JAMA Oncol. 2019;5(10):e191870. doi:10.1001/jamaoncol.2019.1870.
Increasing Diversity in Clinical Trials: Solutions for Overcoming Barriers, Current Problems in Cardiology. Clark L, Regnante, J, Puckrein G et al, Published online Nov 9, 2019.
US Cancer Centers of Excellence
Coordination of operational strategies contribute to enhanced accrual of racial and ethnic minorities in clinical trials
FDA Office of Minority Health and Health Equity (OMHHE) and Yale Center for Clinical Investigation report on Advancing Clinical Trial Diversity through Community Engagement
AACR Disparities Meeting highlights, San Francisco, Sept 2019
About Clinical Trials: FDA’s Office of Minority Health and Health Equity (OMHHE)
All of Us:
Drug Trials Snapshots:
FDA’s Action Plan for FDASIA Section 907:
The FDASIA Sec. 907 Action Plan recommends that medical product applications submitted for marketing approval improve their demographic subgroup data’s completeness, quality, and availability.
Find Me Cure
Future treatments within your reach
The treatments that are already available are not your only option. Inform yourself about clinical trials happening worldwide right now. We are here to provide you free access to future treatments.
Panel discussion from 2019 PHEN annual meeting with Gerren Wilson, PharmD (Genentech) and Jovonni Spinner, MPH (OMHHE)